Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04628637
Other study ID # Clinical-2
Secondary ID
Status Completed
Phase
First received
Last updated
Start date April 16, 2020
Est. completion date October 10, 2020

Study information

Verified date November 2020
Source Kafkas University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Covid-19 infection was declared a global pandemic by WHO on March 11, 2020. GRP78 protein is known to be involved in the intrusion of numerous viruses. Our current study tries to provide some insight into the variation of GRP78 protein levels in patients with Covid-19(-) pneumonia, Covid-19(+) pneumonia, and CT negative Covid-19 infection in comparison to the normal population through a larger number of cases. 42 patients who have Covid-19(-) pneumonia; 72 patients who have Covid-19 infection (30 pneumonia,42 CT negative patients) and 30 patient who have no known diseases (control group) will be included in the study after the clinical and radiological evaluation. Serum GRP78 levels of the subjects will be measured through a commercially available enzyme-linked immunosorbent assay (ELISA) kit.


Description:

Caused by a new type of coronavirus (SARS-CoV-2) that emerged in China in late 2019 and then were imported throughout the world, Covid-19 infection was declared a global pandemic by WHO on March 11, 2020 (1). Covid-19 infection may manifest itself in severe clinical conditions, ranging from viral upper respiratory tract infection to pneumonia, sepsis, septic shock, and even acute respiratory distress syndrome (ARDS), in symptomatic patients . This study tries to provide some insight into the variation of GRP78 protein levels in patients with Covid-19 (-) pneumonia, Covid-19 (+) pneumonia, and CT negative Covid-19 infection in comparison to the normal population through a larger number of cases. The present study is a prospective case-control study, and the required approval was obtained from the Ethics Committee of Pamukkale University prior to the study (60116787-020 / 26598 numbered). The present study will be included the patients who were admitted between April 2020 and June 2020 to Covid-19 pandemic outpatient clinic of the emergency department (ED) with symptoms of upper respiratory tract infection and pneumonia, were asymptomatic, were established to be Covid-19 PCR (+) during contact tracing, and presented to the ED for further examination and treatment. After the required information concerning the study will be provided both to the patient group and to the healthy control group, the written consent forms will be obtained from all the subjects who agreed to participate in the study. The healthy volunteers with no known chronic or acute disease or drug use as well as no recent history of infection will be included study as the control group. Once these subjects will be assessed in accordance with the inclusion and exclusion criteria, they will be divided into three groups as the Covid-19(-) pneumonia group, the Covid-19 infection group, and the healthy control group. Chest CT will performed at the time of admission of the patients to the ED was assessed under the criteria of the Radiological Society of North America Expert Consensus by an emergency physician who followed up the patient clinically. The pneumonia cases will be classified in line with these criteria and recorded in the clinical classification dataset. Complete blood count, C-reactive protein (CRP), creatinine, urea, d-dimer, and ferritin parameters, which are routinely checked during admission to the ED, will be recorded in the dataset. For GRP78 level measurement, after 3 cc blood sample will be taken into a dry tube and centrifuged at 4000 rpm for 10 minutes, its serum section was separated, and the GRP78 level will be analyzed by the Enzyme-Linked Immunosorbent Assay (ELISA) method. In the control group, on the other hand, after 3 cc of blood was drawn into a dry tube, and another 3 cc of blood will be placed into an EDTA tube, the GRP78 level was analyzed through the same methods in the same laboratory. Serum GRP78 levels of the subjects will be measured through a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Human Glucose Regulated Protein 78 (GRP78) ELISA Kit, Sun Long, SL2048Hu, China), as per the manufacturer's protocol. As a result of the power analysis made in line with the presumptions since a similarly-organized reference study did not exist, at least 84 people (min. 28 for each cohort) were needed to achieve 90% power at 95% confidence interval, assuming that the projected effect size would be medium-high (f = 0.4). 42 patients were eventually will be included in the Covid-19 (-) pneumonia group. A total of 72 patients (30 Covid-19 pneumonia; 42 CT-negative Covid-19 infection) will be included in the Covid-19 infection group.


Recruitment information / eligibility

Status Completed
Enrollment 144
Est. completion date October 10, 2020
Est. primary completion date October 1, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Healthy group (Control group) Inclusion Criteria - To have no known acute, subacute or chronic disease history, - Not to not suffer from any infection in the last fortnight, - Not to be on a particular medication - Presenting to the ED with reasons other than infectious complaints .Giving their written consent to participate in the study. Exclusion Criteria: - Diagnosis of kidney and liver failure, - Acute pulmonary embolism, - Chronic inflammatory disease history (rheumatological disease, autoimmune disease), - Pregnancy, - Presence of any cancer diagnosis, - Chronic obstructive pulmonary disease, - Asthma disease - History of cerebrovascular disease Patient Groups; Covid-19 infection Group; Inculusion Criteria .Presenting Whose CT imagings were normal in accordance with the RSNAEC criteria. - To have positive Covid-19 PCR test - To have Covid-19 PCR tests were positive as a result of contact tracing, - Presenting to the ED for further examination. Exclusion Criteria - Diagnosis of kidney and liver failure, - Acute pulmonary embolism - Chronic inflammatory disease history (rheumatological disease, autoimmune disease) - Pregnancy - Presence of any cancer diagnosis - Chronic obstructive pulmonary disease - Asthma disease - History of cerebrovascular disease .To have a CT imagings that is compatible with Covid-19 pneumonia but whose PCR tests were negative. Covid-19 Pneumonia Group Inclusion Criteria - Presenting to the Covid-19 outpatient policlinic of the ED with pneumonia symptoms - To have CT imagings were not compatible with Covid-19 pneumonia in accordance with the .Radiological Society of North America Expert Consensus (RSNAEC) criteria - To have nasopharyngeal swab samples taken in the ED were negative for PCR, and .To give their informed consent to participate in the study. Exclusion Criteria - To have diagnosis of kidney and liver failure, - Acute pulmonary embolism - Chronic inflammatory disease history (rheumatological disease, autoimmune disease)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Serum protein level analysis
Serum GRP78 levels of the subjects were measured through a commercially available enzyme-linked immunosorbent assay (ELISA) kit (Human Glucose Regulated Protein 78 (GRP78) ELISA Kit, Sun Long, SL2048Hu, China), as per the manufacturer's protocol. The detection rate of this kit is 16 pg/mL.

Locations

Country Name City State
Turkey Aylin Koseler Denizli Outside Of The US

Sponsors (3)

Lead Sponsor Collaborator
Kafkas University Acibadem Mehmet Ali Aydinlar University Faculty of Medicine, Pamukkale University Faculty of Medicine

Country where clinical trial is conducted

Turkey, 

Outcome

Type Measure Description Time frame Safety issue
Primary Determination of the change of the serum GRP-78 protein levels in patients who have Covid-19 infection compared to control group The change of the serum levels of the GRP-78 protein levels in patient who have Covid 19 infection compared to control group. It will be determined whether GRP-78 protein level change in Covid-19 infection. 2 months
Primary Determination of the change of the serum GRP-78 protein levels in patients who have Covid-19 infection compared to Covid-19 negative pneumonia group. The change of the serum levels of the GRP-78 protein levels in patient who have Covid 19 infection compared to Covid-19 negative pneumonia group.. It will be determined whether GRP-78 protein level change in Covid-19 (-) pneumonia. 2 months
Secondary Determination of the correlations between laboratory parameters, clinical parameters and radiological parameters Correlationships will be analysed between Complete blood count, C-reactive protein (CRP), creatinine, urea, d-dimer, and ferritin parameters, CURB-65 score, PORT score, symptom duration, CT severity score. 2 months
See also
  Status Clinical Trial Phase
Completed NCT05047692 - Safety and Immunogenicity Study of AdCLD-CoV19-1: A COVID-19 Preventive Vaccine in Healthy Volunteers Phase 1
Recruiting NCT04395768 - International ALLIANCE Study of Therapies to Prevent Progression of COVID-19 Phase 2
Terminated NCT04555096 - A Trial of GC4419 in Patients With Critical Illness Due to COVID-19 Phase 2
Completed NCT04506268 - COVID-19 SAFE Enrollment N/A
Completed NCT04508777 - COVID SAFE: COVID-19 Screening Assessment for Exposure
Completed NCT04961541 - Evaluation of the Safety and Immunogenicity of Influenza and COVID-19 Combination Vaccine Phase 1/Phase 2
Active, not recruiting NCT04546737 - Study of Morphological, Spectral and Metabolic Manifestations of Neurological Complications in Covid-19 Patients N/A
Terminated NCT04542993 - Can SARS-CoV-2 Viral Load and COVID-19 Disease Severity be Reduced by Resveratrol-assisted Zinc Therapy Phase 2
Not yet recruiting NCT04543006 - Persistence of Neutralizing Antibodies 6 and 12 Months After a Covid-19 N/A
Completed NCT04494646 - BARCONA: A Study of Effects of Bardoxolone Methyl in Participants With SARS-Corona Virus-2 (COVID-19) Phase 2
Completed NCT04532294 - Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2/COVID-19) Neutralizing Antibody in Healthy Participants Phase 1
Terminated NCT04581915 - PHRU CoV01 A Trial of Triazavirin (TZV) for the Treatment of Mild-moderate COVID-19 Phase 2/Phase 3
Completed NCT04387292 - Ocular Sequelae of Patients Hospitalized for Respiratory Failure During the COVID-19 Epidemic N/A
Completed NCT04537663 - Prevention Of Respiratory Tract Infection And Covid-19 Through BCG Vaccination In Vulnerable Older Adults Phase 4
Not yet recruiting NCT04527211 - Effectiveness and Safety of Ivermectin for the Prevention of Covid-19 Infection in Colombian Health Personnel Phase 3
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Not yet recruiting NCT05038449 - Study to Evaluate the Efficacy and Safety of Colchicine Tablets in Patients With COVID-19 N/A
Completed NCT04979858 - Reducing Spread of COVID-19 in a University Community Setting: Role of a Low-Cost Reusable Form-Fitting Fabric Mask N/A
Completed NCT04610502 - Efficacy and Safety of Two Hyperimmune Equine Anti Sars-CoV-2 Serum in COVID-19 Patients Phase 2
Active, not recruiting NCT06042855 - ACTIV-6: COVID-19 Study of Repurposed Medications - Arm G (Metformin) Phase 3